MedTrace Logo

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

NCT02587650 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2020-01-27

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well capmatinib, ceritinib, regorafenib, or entrectinib work in treating patients with BRAF/NRAS wild-type stage III-IV melanoma. Capmatinib, ceritinib, regorafenib, or entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Conditions

  • ALK Fusion Protein Expression
  • BRAF wt Allele
  • Invasive Skin Melanoma
  • MET Fusion Gene Positive
  • NRAS wt Allele
  • NTRK1 Fusion Positive
  • NTRK2 Fusion Positive
  • NTRK3 Fusion Positive
  • RET Fusion Positive
  • ROS1 Fusion Positive
  • Stage III Cutaneous Melanoma
  • Stage IIIA Cutaneous Melanoma
  • Stage IIIB Cutaneous Melanoma
  • Stage IIIC Cutaneous Melanoma
  • Stage IV Cutaneous Melanoma

Interventions

DRUG

Capmatinib

Given PO

DRUG

Ceritinib

Given PO

DRUG

Entrectinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Regorafenib

Given PO

Sponsors & Collaborators

Principal Investigators

  • Adil Daud · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-26
Primary Completion
2018-07-12
Completion
2018-07-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02587650 on ClinicalTrials.gov